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Abstract 
Viral progeny of two molecular clones of feline immunodeficiency virus (FIV), 19kl and 19k32, 
were tested in a virus neutralization assay. In this assay the infection of thymocytes with FIV19kl 
was neutralized by serum S1422, derived from an SPF cat 22 weeks after infection with PIV19kl. 
We previously reported that a point mutation at position 560 in hypervariable r gion-5 (HV-5) of 
19kl confers resistance to virus neutralization (Siebelink et al., 1993, J. Viral. 67: 2202-2208). Viral 
progeny of the other molecular clone, FIV19k32, which differs in the envelope protein in only six 
amino acids from 19k1, was not neutralized. In order to map sites involved in virus neutralization we 
constructed chimeric clones by reciprocal exchange of 19kl and 19k32 envelope gene fragments. 
Reciprocal exchange of a 1662 bp fragment, encoding almost he whole surface protein, which differs 
in five amino acids between these two clones, resulted in exchange of the phenotype. Amino acids of 
the envelope protein of 19kl and 19k32, in which these clones differ, were substituted by point 
mutation. We demonstrated that one of these mutations, asubstitution of leucine to serine at position 
483 in HV-4, also conferred resistance of 19kl to neutralization by serum S1422. 
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1. Introduction 
Virus neutralizing (VN) antibodies are generally accepted to play an important role in 
the protective immune response against infection with lentiviruses including human immu- 
nodeficiency virus (HIV) (Berman et al., 1990; Prince et al., 1991; Emini et al., 1992), 
simian immunodeficiency virus (SIV) (Lewis et al., 1993) and feline immunodeficiency 
virus (FIV) (Hohdatsu et al., 1993). However these VN antibodies are incapable of 
eliminating the virus from humans or animals. Infection thus results in persistence of the 
virus in the host leading to a continuous interaction between the virus and the immune 
system (Fauci, 1988). Genetic variation allows the virus to generate mutants which are no 
longer recognized by VN antibodies: so-called escape mutants. Such antigenic variation 
has been described in several lentiviral systems including Equine infectious anaemia virus 
(EIAV), Maedi-Visna virus, HIV and SIV (Narayan et al., 1977; Montelaro et al., 1984; 
Albert et al., 1990; Franchini et al., 1990; Burns et al., 1993; Joag et al., 1993). For HIV as 
well as for FIV it has been shown that one single point mutation in the envelope gene can 
confer resistance to virus neutralizing antibodies in vitro (Reitz et al., 1988, Siebelink et 
al., 1993). In the present study, it is shown that two independently arisen single point 
mutations in two different regions of the surface glycoprotein of FIV can each confer 
resistance to virus neutralizing antibodies present in a polyclonal serum. One of these 
mutations was generated in vitro whereas the other is observed in vivo. 
2. Materials and methods 
2.1. Molecular clones and virus 
Replication competent molecular clones 19kl and 19k32 were obtained directly from 
bone marrow cells of a naturally FIV infected cat as described previously (Siebelink et al., 
1992). Viral progeny of 19kl (FIVl9kl) and 19k32 (FIV19k32) were obtained by trans- 
fection of Crandell feline kidney (CrFK) cells followed by cocultivation with feline periph- 
eral blood mononuclear cells ( PBMCs) as described previously (Siebelink et al., 1992). 
PBMCs infected with FIV19kl were cultured in continuous presence of serum from Cat 
No. 14 (see below) to obtain the VN escape mutant as described previously (Siebelink et 
al., 1993). 
2.2. Sera 
A lo-week-old SPF cat (Cat No. 14) was infected with FIV19kl by intraperitoneal 
inoculation of lo2 TCID,,. Serum of Cat No. 14 was taken prior to infection (preserum) 
and at 22 weeks post infection (designated serum S1422). Serum from a naturally FIV 
infected cat, A’dam19 was designated serum AM19 (Siebelink et al., 1992). Serum of a 
non-infected SPF cat was used as a control serum (SPF serum). All sera were heat inacti- 
vated for 1 h at 56°C prior to use. 
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2.3. Reverse transcriptase assay 
Reverse transcriptase (RT) activity was determined as previously described (Siebelink 
et al., 1992). 
2.4. Virus neutralization assay 
VN antibodies were determined as previously described (Siebelink et al., 1993). In brief, 
450 ~1 of diluted virus stocks containing a RT activity of 5 X lo4 counts per min per ml 
were incubated with 50 ~1 of a serum sample. After 60 min at 37°C 500 ~1 Con A and IL- 
2 stimulated PBMC ( 106) were added. After 12 days the culture supernatant was tested for 
presence of virus by RT activity. The virus neutralization index (VN index) was calculated 
by: 
RT activity of the culture with SPF serum 
RT activity of the culture with serum S 1422 
Virus neutralization was considered positive when the VN index was more then 3, based 
on a survey of sera of non-infected cats (not shown). 
2.5. Sequence analysis 
The sequences of the envelope genes of the molecular clones 19kl and 19k32 and of the 
VN escape mutant 19klesc have previously been described (Siebelink et al., 1992, 1993). 
2.6. Generation of chimeric clones 
Chimeric clones of 19kl and 19k32 were constructed using the 5’- and 3’- subclone of 
19kl and 19k32 as described previously (Siebelink et al., 1993). Briefly, molecular clones 
of 19kl and 19k32 were digested with SaA and SphI and the fragments were subcloned. 
The 5’ subclone contains gag and 5’ part of pal and the 3’ subclone contain the 3’ part of 
pal and enu. The chimeric clones are schematically represented in Fig. 1. Chimere 19kl- 
560 is obtained by site directed mutagenesis as described previously for 19klmut2 (Sie- 
belink et al., 1993). The 3’ subclones of 19kl and 19k32 were used to exchange internal 
1662 bp KpnI fragments between 19kl and 19k32. These chimeras are designated 
19klKK32 (19kl containing the KpnI fragment of 19k32) and 19k32KKl (19k32 con- 
taining the KpnI fragment of 19kl). 
The 1662 bp KpnI fragment of 19kl and 19k32 was subcloned into pUC19 (designated 
3’ KK-subclone of 19kl and 19k32, respectively) and used to exchange the 144 bp NsiI- 
Mst2 fragment. These subclones were designated 19klNM32 ( 19kl containing the NsiI- 
Mst2 fragment of 19k32) and 19k32NMl (19k32 containing the NsiI-Mst2 fragment of 
19kl). 
The 3’ KK-subclones of 19kl and 19k32 were used for the substitution of single nucle- 
otides by site directed mutagenesis using the transformer site directed mutagenesis kit 
(Clontech laboratories, USA). For the mutagenesis six oligonucleotides were designed. 
19kl 
19kl-560 
19k32 
19klKK32 
19k32KKl 
19kl NM32 
19k32NMl 
1 Sk1 -222 
19kl-454 
19kl-483 
19k32-222 
19k32-454 
19k32-483 
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These oligonucleotides are listed in Table 1. The mutagenesis was confirmed by sequence 
analysis. 
The 1662 bp KpnI fragments from the 3’ KK subclones of 19kl and 19k32 in which 144 
bp NsiI and Mst2 fragments were exchanged or single nucleotides were mutated by site. 
directed point mutation were cloned into the corresponding 3’subclone of 19kl and 19k32, 
respectively; 2.5 pg of each of the 3’ subclones and the 5’ subclones were mixed, digested 
with sph1 and ligated. After digestion with SalI the constructs were transfected into Crandell 
feline kidney cells (CrFK) as previously described (Siebelink et al., 1992). Virus produc- 
tion was rescued by cocultivation of transfected cells with Con A and IL-2 stimulated PBMC 
for 3 days. Cultures were monitored for syncytium formation of PBMC and RT activity in 
the culture supernatant. When RT activity could be measured culture supernatant was filtered 
through an 220 nm filter and stored in aliquots at - 135°C. 
POL 
GAG m ENV 
flanking I -I D flanking 
sequence sequence 
I 
12 34 5 
v mutation 
-- K->Q 
R -> s 
N -> D 
L -> s 
9 s -> R 
T D -> N 
.‘I<,.. s -> L 
VN-index 
42 
2 
2 
1 
43 
82 
1 
102 
89 
1 
1 
2 
1 
Fig. 1. Schematic representation of the chimeric FIV clones with the VN index (see text for details). The uppermost 
bars represent the major open reading frames gag, pol and env. The black boxes represent the hypervariable 
regions in the envelope protein. The patterns are corresponding to the parental clones. Individual point mutations 
are indicated with ‘ v ‘. Restriction enzyme cleaving sites are indicated as: K, KpnI; M, A4sR; N, WI; S, Sall; Sp, 
SphI. 
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Table 1 
Oligonucleotide sequences used for site directed mutagenesis 
Oligo Sequence Chimere name 
l-666 5’-CAAATATAAGTATACAAGAGG-3’ 19kl-222 
l-1360 5’-CAAAACATCATGATGAAGCAAGG-3’ 19kl-454 
1-1448 5’-CACAAAATG’I-ITCAGGTGC-3’ 19k1-483 
32-666 5’-CAAATATAAGAATACAAGAGGG-3’ 
32- 1360 5’-CAAAACATCATAATGAAGCAAGG-3’ 
32-1448 5’-CACAAAATGTT’ITAGGTGC-3’ 
The mutations are indicated in bold. 
19k32-222 
19k32-454 
19k32-483 
2.7. Synthesis and reaction of peptides with sera 
Twelve-mer peptides with an overlapping sequence of 11 amino acids were synthesized 
and analyzed for their reactivity with sera as previously described (Geijsen et al., 1984). 
The amino acid sequences of the peptides were based on the amino acid sequences of the 
envelope proteins of clones 19kl,19k32 and 19klesc between amino acid position 549 and 
583 (HV-5) and between the amino acid positions 472 and 494 (HV-4). Three 12-mer 
control peptides with an overlapping sequence of 8 amino acids were synthesized according 
to the epitope between position 596 and 616 as previously described (Avrameas et al., 
1992). 
3. Results 
3.1. Neutralization of FIV19k1, FIVl9k32 and FIV19klesc by serum S1422 
Viral progeny of 19kl and 19k32 and the escape mutant FIV19klesc were tested in a 
VN assay with serum S1422. An SPF serum was used as a control. Virus replication as 
determined by RT activity was demonstrated in all cultures in the presence of SPF serum. 
In the presence of serum S1422 only in the cultures of FIVl9k32 and FIV19klesc and not 
in the culture of FIV19kl virus replication could be demonstrated (Table 2). 
3.2. Sequence analysis 
Virus neutralizing antibodies which interfere with viral entry, are generally directed to 
the envelope proteins. Therefore the envelope protein sequences of FIV19k1, FIV19k32 
and FIV19klesc were compared. Amino acid sequence differences are listed in Table 3. 
Comparison of the envelope protein sequences of 19kl and 19k32 showed the presence of 
six substitution mutations of which one is located in HV-4 and two are located in HV-5. 
The other three are found in the more conserved regions: one between HV-2 and HV-3, one 
between HV-4 and HV-5 and one in the transmembrane (TM) part of env. 
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3.3. Virus neutralization of chimeric clones 
Viral progeny of the parental clone 19k1, 19k32 and the chimeric lones were incubated 
with serum S1422 or SPF serum prior to infection of thymocytes. The results of this 
experiment are similar to a number of previous experiments in which each of the chimeric 
clones were tested separately for neutralization by serum S 1422. RT activity was measured 
12 days post infection. RT activity could be measured in all the control cultures. As shown 
previously (Siebelinket al., 1993) FIV19kl-560 was not neutralized by serum S 1422 (Fig. 
1). This virus has a lysine to glutamine substitution mutation at position 560 in HV-5. 
Reciprocal exchange of a 1662 bp KpnI fragment between 19kl and 19k32 resulted in 
the chimeric clones 19klKK32 and 19k32KKl. Chimeric clone 19klKK32 was not neu- 
tralized by serum S1422 whereas chimeric clone 19k32KKl was neutralized by serum 
S 1422 (Fig. 1) indicating that an epitope of the surface protein is involved in neutralization. 
Reciprocal exchange of HV-5 by the exchange of the 144 bp NsiI-Mst2 fragment resulted 
in the chimeric lones 19klNM32 ( 19kl containing the MI-Mst2 fragment of 19k32) and 
19k32NMl (19k32 containing theNsiI-Mst2 fragment of 19kl). Chimera 19klNM32 was 
neutralized with serum S 1422 whereas 19k32NMl was not neutralized with serum S1422 
(Fig. 1) indicating that a site outside I-IV-5 is also involved in neutralization. 
Therefore, the other three amino acids which are different between 19kl and 19k32 were 
substituted separately by site directed mutagenesis. The mutated clones of 19kl were 
designated 19kl-222 (position 222, Arg to Ser), 19k1454 (position 454, Asn to Asp) 
Table 2 
Virus neutralization of molecular clones 19kl and 19k32 and the VN escape mutant 19klesc with serum S1422 
and SPF serum 
Virus RT activity after neutralization with VN index 
Serum S 1422 SPF serum 
FIV19kl 3636 174990 48 
FIV19klesc 65925 52845 1 
FIV19k32 104658 58782 1 
Table 3 
Differences between 19k1, 19k32 and 19klesc in the envelope protein 
HV-region Position 
2-3 222 
4 454 
4-5 483 
5 555 
5 556 
5 557 
5 560 
TM 741 
19kl 
Arg 
Asn 
LeU 
Asn 
Asn 
His 
LYS 
Ala 
19k32 
Ser 
Asp 
Ser 
LYs 
Asn 
Tyr 
LYs 
Asp 
19klesc 
Arg 
Asn 
LeU 
Asn 
Thr 
His 
Gln 
Ala 
K.H.J. Siebelink et al. /Veterinary Immunology and Immunopathology 46 (1995) 51-59 57 
and 19k1483 (position 483, Leu to Ser) . The corresponding clones of 19k32 were recip- 
rocally substituted and designated accordingly. FIV 19kl-222 and FIV 19k1-454 were 
neutralized by serum S 1422 whereas FIV 19k1483 could not be neutralized indicating that 
the leucine to serine substitution at position 483 can also confer resistance to virus neutral- 
ization by serum S1422. FIV 19k32-222, FlV 19k32-454 and FIV19k32-483 could not be 
neutralized by serum S1422. 
3.4. Pepscan analysis 
Twelve-mer peptides representing the amino acid sequence of the clones 19kl and the 
escape mutant 19klesc between amino acid positions 549 and 583 and between the amino 
acid positions 472 and 494 were analyzed for reactivity with serum S1422, serum from a 
naturally FIV infected cat Adam19 (serum AM19) and SPF serum. As a control for the 
pepscan procedure three 1Zmer peptides spanning, with an overlap of eight amino acids, a 
previously described linear epitope on the envelope protein of FIV (from amino acid 
position 596 to 616) were scanned with serum S1422, serum AM19 and SPF serum. No 
reactivity in these sera was detected with the HV-5 peptides and HV-4 peptides whereas 
serum S1422 and serum AM19 did react in the control pepscan (not shown) suggesting 
that no linear B-cell epitope in the C-terminal half of HV-5 is recognized by serum S 1422 
and serum AM19. 
4. Discussion 
In the present report we have demonstrated that two independent single amino acid 
substitutions can confer resistance to virus neutralizing antibodies present in a polyclonal 
cat serum. Neither of the two regions in which these mutations occurred demonstrated 
reactivity with this serum in a pepscan analysis. This indicates that the recognized epitope( s) 
cannot be mimicked with linear synthetic peptides and consequently that the recognized 
epitopes are by themselves not linear. The finding that both mutations, occurring at two 
regions in the surface glycoprotein that are approximately 80 amino acids apart, lead to 
escape from neutralization would then indicate that these regions may well be invotved in 
the formation of a single conformational epitope, in which they would be in close proximity 
to each other spatially. Point mutations at each of these regions would disturb the confor- 
mation, resulting in loss of binding by the antibodies present in the serum that recognize 
the aforementioned conformational epitope. An alternative explanation would be, that both 
the mutations caused a major change in the overall conformation of the surface glycoprotein 
thus allowing a number of different VN epitopes to change their conformation or to hide 
from recognition by VN antibodies. Serum S1422 was collected from Cat No. 14 at 5 
months post infection with FIV19kl. Using our system we can only find evidence for the 
existence of one major neutralization epitope. However, this finding does not preclude the 
presence of VN antibodies reactive to other envelope regions which may be detected in 
other or modified culture systems. It is interesting to note that the two regions in which the 
mutations have been observed are both located in the C-terminal half of the surface glyco- 
protein. For HIV-l it has been demonstrated that it binds its cellular receptor CD4 with a 
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conformationally formed binding site, to which especially regions at the C-terminal half of 
gp120 contribute. Antibodies directed at this conformational CD4-binding site neutralize 
HIV- 1. It is conceivable that our data, indicating the presence of a conformational virus 
neutralizing epitope in the C-terminal half of the surface glycoprotein, likewise point to the 
presence of a similar receptor binding site formed in this region of the FIV envelope. 
The change in VN phenotype between the progenies of clones 19kl and 19k32, which 
could be mimicked by introducing only one of the naturally occurring genetic differences 
between these clones namely a leucine to serine substitution at position 483, suggests that 
19k32 has resulted from a mutant of FIV that had escaped from antibodies that neutralized 
FIV19kl. Clones 19kl and 19k32 coexisted in the bone marrow cells of cat AM19 (Sie- 
belink et al., 1992). The viral progeny of these clones exhibit differential susceptibilities to 
VN antibodies which indicates that the generation of VN escape mutants is an ongoing 
process in vivo in FIV infected cats. The fact that we could not make FIV 19k32 susceptible 
to VN by serum S1422 through the serine to leucine substitution at position 483 indicates 
that these two viruses differ from each other at more than one position contributing to the 
pertinent conformational neutralizing epitope. A combination of two or more mutations 
may induce VN susceptibility in FIV 19k32. This work is presently in progress. 
The leucine to serine substitution mutation at position 483 introduces a potential N-linked 
glycosylation site at position 48 1. N-linked glycosylation has been postulated to mask viral 
neutralizing epitopes (Alexander and Elder, 1984) or hinder binding of VN antibodies 
(Davis et al., 1990). The above postulated conformation of the VN epitope could be masked 
by the introduced carbohydrate group or the carbohydrate group can actually by itselfchange 
the conformation of the VN epitope. Genetic exchange experiments and point mutations 
will reveal whether the N-linked glycan plays indeed a role in the escape mechanism. 
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